FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

HGH Fragment 176-191

HGH Frag / Fragment 176-191

Weight Loss & Metabolic

HGH Fragment 176-191 is a synthetic peptide corresponding to amino acids 176-191 of the C-terminal region of human growth hormone, specifically isolated for its lipolytic (fat-burning) properties without the growth-promoting or diabetogenic effects of full-length HGH. It was identified through research at Monash University demonstrating that this specific fragment retains the fat-metabolizing activity of growth hormone while lacking IGF-1 stimulating capacity. Its primary research applications focus on targeted fat loss, obesity treatment, and metabolic regulation without the broader hormonal effects of full GH administration.

作用机制

The lipolytic fragment of human growth hormone encompassing amino acids 176-191. Promotes fat metabolism through beta-3 adrenergic receptor pathways.

研究协议

仅供研究使用,非医疗建议。

Research protocols use 250-500mcg twice daily, subcutaneous. Administer on empty stomach.

研究笔记

Clinical Research Status

HGH Fragment 176-191 (also designated AOD-9604 in its modified form) has undergone Phase II clinical trials for obesity conducted by Metabolic Pharmaceuticals Limited in Australia. The modified version AOD-9604 received FDA GRAS (Generally Recognized as Safe) status in 2014 for use in food products, though it is not approved as a pharmaceutical. Research interest continues in the peptide community for body composition applications, though formal clinical development has largely stalled since initial trial results showed modest efficacy in weight loss endpoints.

Key Published Findings

Original research by Ng and Borstein at Monash University demonstrated that Fragment 176-191 stimulates lipolysis in adipose tissue at concentrations 12.5 times more potent than full-length HGH on a molar basis. Clinical trials with the AOD-9604 form showed statistically significant weight loss versus placebo over 12 weeks, with preferential reduction of abdominal fat. Importantly, studies confirmed that the fragment does not induce insulin resistance, does not elevate IGF-1 levels, and does not promote long bone growth, effectively isolating the lipolytic mechanism from other GH effects.

Safety Profile

Clinical trial data demonstrated excellent tolerability with no serious adverse events attributed to the peptide at studied doses. The compound does not affect blood glucose or insulin sensitivity, differentiating it significantly from exogenous growth hormone administration. As it does not stimulate IGF-1, theoretical cancer risk concerns associated with elevated growth factors do not apply to this fragment.

Drug Interactions & Contraindications

No significant drug interactions have been identified in clinical studies, consistent with its narrow mechanism of action on adipose tissue. Concurrent use with exogenous growth hormone may be redundant, as both compounds act on the same lipolytic pathway. Caution is theoretically warranted in individuals with extremely low body fat, and the compound should not be used by individuals with active eating disorders.

Comparison to Related Compounds

Unlike full-length HGH which stimulates growth, IGF-1 production, and can cause insulin resistance, Fragment 176-191 specifically and exclusively targets fat metabolism. AOD-9604 is a modified version with a tyrosine residue added to position 176 for improved stability, and the two are often conflated in community discussions. CJC-1295 and GHRP combinations stimulate endogenous GH release (which includes lipolytic effects) but also produce all other GH-mediated effects including potential insulin resistance and IGF-1 elevation.

Community Observations

Users typically administer Fragment 176-191 at 250-500mcg subcutaneously 1-2 times daily, ideally on an empty stomach and separated from food by 30+ minutes to avoid insulin-mediated interference with lipolysis. Reports suggest best results when combined with fasted cardio and moderate caloric deficit, with effects becoming noticeable over 4-8 weeks of consistent use. The community generally considers it a mild but well-tolerated fat loss agent, noting that dramatic results require simultaneous dietary discipline and that it works synergistically with other lipolytic compounds.

半衰期

~15-20 minutes

复溶

Bacteriostatic water (BAC)

存储

冻干

Refrigerate 2-8C up to 12 months.

复溶后

Refrigerate 2-8C. Use within 21 days.

美国法律状态

Research chemical (not FDA-approved)

又称作

HGH FragFragment 176-191

常见问题

什么是 HGH Fragment 176-191?

HGH Fragment 176-191 is a synthetic peptide corresponding to amino acids 176-191 of the C-terminal region of human growth hormone, specifically isolated for its lipolytic (fat-burning) properties without the growth-promoting or diabetogenic effects of full-length HGH. It was identified through research at Monash University demonstrating that this specific fragment retains the fat-metabolizing activity of growth hormone while lacking IGF-1 stimulating capacity. Its primary research applications focus on targeted fat loss, obesity treatment, and metabolic regulation without the broader hormonal effects of full GH administration.

HGH Fragment 176-191 如何起作用?

The lipolytic fragment of human growth hormone encompassing amino acids 176-191. Promotes fat metabolism through beta-3 adrenergic receptor pathways.

HGH Fragment 176-191 在美国的监管状态是什么?

Research chemical (not FDA-approved)

HGH Fragment 176-191 的半衰期是多少?

~15-20 minutes

HGH Fragment 176-191 还有哪些名称?

HGH Frag, Fragment 176-191

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明